Cerebras Enables Notion to Deliver Real-Time Enterprise Search for 100+ Million Workspace Users
By running enterprise search on Cerebras, Notion delivers the speed and scale required for modern knowledge work—streaming results in under 300 milliseconds, with no lag and no latency spikes.
Share
With more than 100 million users worldwide, Notion is redefining productivity for teams across the globe. Now, by running enterprise search on Cerebras, Notion delivers the speed and scale required for modern knowledge work—streaming results in under 300 milliseconds, with no lag and no latency spikes.
'For Notion, productivity is everything. Cerebras gives us the instant, intelligent AI needed to power real-time features like enterprise search, and enables a faster, more seamless user experience,' said Sarah Sachs, AI Lead at Notion.
'Cerebras Inference enables Notion users to instantly pull insights from all enterprise documents, including Wikis, project documents, meeting notes and more. These docs will now think as fast as you do,' said Angela Yeung, VP of Product, Cerebras. 'Notion AI for Work can handle hundreds of millions of pages without slowdowns by leveraging Cerebras' inference technology.'
Notion AI for Work, featuring Cerebras' inference capabilities, is available for business and enterprise customers. For more information, please visit www.notion.com.
About Cerebras Systems
Cerebras Systems is a team of pioneering computer architects, computer scientists, deep learning researchers, and engineers of all types. We have come together to accelerate generative AI by building from the ground up a new class of AI supercomputer. Our flagship product, the CS-3 system, is powered by the world's largest and fastest commercially available AI processor, our Wafer-Scale Engine-3. CS-3s are quickly and easily clustered together to make the largest AI supercomputers in the world, and make placing models on the supercomputers dead simple by avoiding the complexity of distributed computing. Cerebras Inference delivers breakthrough inference speeds, empowering customers to create cutting-edge AI applications. Leading corporations, research institutions, and governments use Cerebras solutions for the development of pathbreaking proprietary models, and to train open-source models with millions of downloads. Cerebras solutions are available through the Cerebras Cloud and on-premises. For further information, visit cerebras.ai or follow us on LinkedIn, X and/or Threads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Introducing Cambridge Forum 2025: Tech for Good
CAMBRIDGE, England--(BUSINESS WIRE)-- Cambridge Forum 2025, themed 'Tech for Good', is set to bring together global technology leaders, development innovators, policymakers, entrepreneurs, and academics in Cambridge this September. This two-day event discusses technology as a force for inclusive empowerment and positive social impact. Our Vision: From Underserved to Unstoppable At Cambridge Forum, we believe that technology can transform lives—especially in underserved communities. Rooted in Cambridge's academic and innovation ecosystem, we will foster collaboration across technology, development, academia, policy, and the private sector to bring solutions to the world's pressing challenges. Taking place in the historic city of Cambridge—a global hub for intellectual discovery—the Forum aims to be a permanent platform for inclusive collaboration across disciplines, sectors, and geographies. 'We believe the world's toughest challenges can't be solved in silos. Cambridge Forum offers a shared space to design, build, and scale innovation for good,' said Dr. Ehab Shanti, Founding Director of Cambridge Forum. 'AI undoubtedly presents enormous derivative challenges, but it also creates significant opportunities. Cambridge Forum will explore both,' he added. Cambridge Forum 2025 will feature a high-impact line-up of world-class speakers and changemakers, including: Marty Neumeier – Highly influential American author, designer, and business advisor focused on the intersection of design, branding, and innovation will deliver a session on 'Goodness as Corporate DNA'. Jaideep Prabhu – Co-author of Jugaad Innovation: Think Frugal, Be Flexible, will deliver a session on" Frugal Innovation: Leveraging Digital Public Infrastructure for Inclusive Artificial Intelligence'. Dr. Gareth Corbett, Chief Medical Officer, Onion AI will discuss, 'Tech for Good, The Case of AI and Health'. Henning Grosse Ruse Khan - Professor of Law at the University of Cambridge will discuss, 'Can We Regulate AI to Prevent Harm?'. Why It Matters In a time of global complexity and rapid technological advancement, we aim to ensure no one is left behind. By fostering cross-sector collaboration and offering practical tools, Cambridge Forum helps turn big ideas into real-world solutions to address the world's most pressing issues. About Cambridge Forum Cambridge Forum is a training and knowledge-sharing event that provides participants with a unique opportunity to learn. Through practical training and real-world applications, we will discuss how to harness advanced technology in AI and Insurtech to address the world's most pressing challenges and serve underserved communities.
Business Wire
2 hours ago
- Business Wire
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Yahoo
3 hours ago
- Yahoo
EZVIZ Reshapes Front Door Security with the Y3000FVP Plus, the Flagship Smart Lock to Integrate Facial and Palm Vein Recognition for Ultimate Protection and Convenience
DUBAI, United Arab Emirates, August 18, 2025--(BUSINESS WIRE)--EZVIZ, a global leader in smart home security, proudly announces the launch of its latest flagship innovation, the Y3000FVP Plus, a premium smart lock that combines facial recognition and palm vein recognition for unbeatable security and convenience. With next-generation AI capabilities, multiple unlocking methods, and an enhanced safety design, the Y3000FVP Plus promises to provide homeowners with an unparalleled level of protection, ease of access, and peace of mind. "We're giving homeowners a smarter and more reliable way to protect their home," said Grant Chen, Vice President of EZVIZ. "With the Y3000FVP Plus, EZVIZ leverages the most cutting-edge technology to protect what matters most." Marking its hot debut in the Middle East, EZVIZ has captured the locally upscaling demand for elegant, intelligent home solutions, while witnessing the lack of a hassle-free user experience. Combining product quality with exceptional customer support, EZVIZ has developed its network of professional installers and related services, so the overall user journey can go as smoothly as possible from purchase, installation, and after-sales care. At the heart of the Y3000FVP Plus are its two industry-leading unlocking methods. This smart lock uses localized 3D data processing to guarantee only live, real-time faces are detected, even adapting to various lighting conditions. It reliably identifies individuals between 1.2m and 2m, unaffected by hairstyle, makeup, or glasses. For added convenience, especially in situations where users might be wearing a mask or carrying items, palm vein recognition provides a secure, forgery-resistant alternative. Both methods are powered by a 12nm AI chip and dual-core CPU, ensuring swift, accurate recognition. Furthermore, there are multiple user-friendly access options, from fingerprint scanning for quick entry, to passcodes for guest access, and even app-based remote unlocking for those constantly on the move. Beyond convenience, the Y3000FVP Plus prioritizes front door security. Equipped with a 1080p camera featuring ultra-wide viewing and night vision, the lock ensures clear monitoring at any time of the day or night. Users receive real-time alerts when movement is detected and can review recorded events. For enhanced protection, the lock is fortified with anti-theft features, such as an automatic siren to deter tampering, a C-grade cylinder to block unauthorized access, and long passcodes to safeguard against guessing attempts. View source version on Contacts Charlene Lilixiaolan15@ Sign in to access your portfolio
